Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Blood test vs CT to detect recurrence of colorectal cancer

This week's issue of the Journal of the American Medical Association examines the effect of 3 to 5 Years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer.

News image

Intensive follow-up after surgery for colorectal cancer is common practice but is based on limited evidence.

Professor David Mant and colleagues from the United Kingdom assessed the effect of scheduled blood measurement of carcinoembryonic antigen (CEA) and computed tomography (CT) as follow-up to detect recurrent colorectal cancer treatable with curative intent.

The research team performed a randomized clinical trial in 39 National Health Service hospitals in the United Kingdom.

The team recruited 1202 eligible participants between 2003 and 2009 who had undergone curative surgery for primary colorectal cancer, including adjuvant treatment if indicated, with no evidence of residual disease on investigation.

Participants were randomly assigned to 1 of 4 groups, including 300 patients in the CEA only group, 299 in the CT only group, 302 in the CEA+CT group, and 301 patients in the minimum follow-up group.

Surgical treatment of recurrence with curative intent was 7% in the CEA group
Journal of the American Medical Association

Blood CEA was measured every 3 months for 2 years, then every 6 months for 3 years.

CT scans of the chest, abdomen, and pelvis were performed every 6 months for 2 years, then annually for 3 years.

The team reported that the minimum follow-up group received follow-up if symptoms occurred.

The team's main outcomes included surgical treatment of recurrence with curative intent.

The researcher's secondary outcomes were mortality, time to detection of recurrence, and survival after treatment of recurrence with curative intent.

After a mean 4 years of observation, cancer recurrence was detected in 199 participants overall.

The research team treated 71 of 1202 participants for recurrence with curative intent, with little difference according to Dukes staging.

Surgical treatment of recurrence with curative intent was 2% in the minimum follow-up group, 7% in the CEA group, 8% in the CT group, and 7% in the CEA+CT group.

Compared with minimum follow-up, the absolute difference in the percentage of patients treated with curative intent in the CEA group was 4%, in the CT group was 6%, and in the CEA+CT group was 4%.

The team observed that the number of deaths was not significantly different in the combined intensive monitoring groups vs the minimum follow-up group.

Professor Mant's team concluded, "Among patients who had undergone curative surgery for primary colorectal cancer, intensive imaging or CEA screening each provided an increased rate of surgical treatment of recurrence with curative intent compared with minimal follow-up."

"There was no advantage in combining CEA and CT."

"If there is a survival advantage to any strategy, it is likely to be small."

JAMA 2014; 311(3): 263-270
16 January 2014

Go to top of page Email this page Email this page to a colleague

 31 October 2014

Advanced search
 31 October 2014 
C. difficile infection with metronidazole
 31 October 2014 
Pediatric NAFLD
 31 October 2014 
Pregnancy complications in celiac disease
 30 October 2014 
Constipation and colorectal cancer
 30 October 2014 
Costs in newly diagnosed patients with chronic constipation
 30 October 2014 
Cirrhosis in women
 29 October 2014 
Quality of life after infection with E. coli
 29 October 2014 
IBS in primary care
 29 October 2014 
Sensorimotor activity in functional dyspepsia
 28 October 2014 
Risk factor for smaller final height in Crohn's
 28 October 2014 
Increased bile acid synthesis in IBS-diarrhea
 28 October 2014 
Successful radiofrequency ablation for Barrett’s
 27 October 2014 
Celiac disease and type 1 diabetes
 27 October 2014 
Gluten awareness among chefs
 27 October 2014 

PPI-responsive esophageal eosinophilia

 24 October 2014 
Olmesartan-associated enteropathy
 24 October 2014 
Opioid use in IBD
 24 October 2014 
NSAIDs and Barrett's risk
 23 October 2014 
Outcomes in hospitalized patients with GI bleeding
 23 October 2014 
Thiopurines and colorectal cancer risk in IBD
 23 October 2014 
Advancing the field of functional GI disorders
 22 October 2014 
Early-TIPSS placement prevents rebleeding
 22 October 2014 
Liver fibrosis prognostic biomarkers in type-2 diabetes
 22 October 2014 
H pylori eradication with multiple drug resistance
 21 October 2014 
Alcohol and Barrett's
 21 October 2014 
Scoring systems for critically ill cirrhotic patients
 21 October 2014 
Aspirin and NAFLD
 20 October 2014 
Adalimumab in secondary loss of response in Crohn's
 20 October 2014 
Drug resistant H pylori eradication
 20 October 2014 
Omega-3 and colorectal cancer
 17 October 2014 
Tumor necrosis factor-alpha inhibitors and pregnancy in IBD
 17 October 2014 
Colorectal testing utilization
 17 October 2014 
Fecal microbiota composition in postinfectious IBS
 16 October 2014 
Risk of Barrett's esophagus
 16 October 2014 
Aspirin tablets and colorectal tumours
 16 October 2014 
Economic impact of IBS
 15 October 2014 
Achieving competency at colonoscopy
 15 October 2014 
Preparation for surgery in Crohn's
 15 October 2014 
Bowel preparations
 14 October 2014 
Colorectal testing utilization in commercially insured US adults
 14 October 2014 
Sustained response to infliximab
 14 October 2014 
IBD management during pregnancy
 13 October 2014 
Predicting PPI response in GERD-related cough
 13 October 2014 
Probiotics in IBS
 13 October 2014 
Use of azathioprine in IBD
 10 October 2014 
NAFLD in the Veterans Administration population
 10 October 2014 
Liver injury from herbals and dietary supplements
 10 October 2014 
Predictors for cecal insertion time
 09 October 2014 
Methotrexate-related liver disease and metabolic syndrome
 09 October 2014 
Biomarkers of acetaminophen overdose patients
 09 October 2014 
Postoperative adhesions in digestive surgery
 08 October 2014 
Gluten introduction in high risk children
 08 October 2014 
Vitamin D and HCC
 08 October 2014 
Feeding intervention in celiac disease infants
 07 October 2014 
Infliximab in pediatric perianal Crohn's
 07 October 2014 
Omega-3 and NAFLD
 07 October 2014 
Endoscopic submucosal dissection in the colorectum 
 06 October 2014 
Clinical indications for computed tomographic colonography
 06 October 2014 
Certolizumab pegol in the treatment of Crohn's
 06 October 2014 
Costs of telaprevir therapy for Hep C

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us